

Dear visitor,

let me introduce Emirates Anticancer Pharmaceuticals (EAP), a young biotechnology company operating in the Middle East in United Arab Emirates.

Our main objective is the intention of development and production of new non-generic anticancer drugs built on our own new principles, new ideas. The main subject of the research are destructors of cellular channels, which are specific supramolecular substances with the ability to specifically bind to certain specific cellular channels to influence the metabolism and career and life functions of cells. This principle is so unique and mounting that allows us to formulate solutions how to develop new concepts of future therapeutics against a large variety of cancer.

The strength of our company is also in the care we provide to devote of a developing of coordinated cooperation between like-minded research and development entities, which have unique technologies, which, in combination with our technology, is reached into the desired synergism. Therefore, our company responsibly committed to theses of the Nanobots SIG consortium, which EAP is a full member of, and from action there the company expects the availability of nano-carriers for clinical trials of our anti-cancer prepares.

If you are interested in cooperation or you are interested in further details, please do not hesitate to contact me.



Raffat El Sayed
Emirates Anticancer Pharmaceuticals (CEO)

